A series of novel podophyllotoxin derivatives was synthesized by coupling 4E-amino-4c-demethyl-4-desoxypodophyllotoxin (3a) or 4E-amino-4-desoxypodophyllotoxin (3b) with N-substituted 5-formylindole (2a-h). Their structures were identied by spectroscopic techniques. These novel derivatives were evaluated for cytotoxicity in vitro against HepG2 and HeLa cell lines. Compared with etoposide, most of the compounds showed more potent cytotoxicities against two tumor cell lines. Judging from the IC 50 values, compound 5n is a promising agent, which is about 15 and 5 times more toxic than etoposide against HepG2 and HeLa cell lines, respectively.Podophyllotoxin is a lignan with potent antiviral and cytotoxic properties [1]. These remarkable properties make podophyllotoxin an important lead compound for the development of new therapeutic agents. Extensive structural modifications of podophyllotoxin have been carried out, which culminated in the clinical introduction of two semisynthetic glucoconjugate analogues of etoposide and teniposide. The chemical modifications lead to the change in the mechanism of action of these lignans, wherein podophyllotoxin acts as antimicrotubule agent, whereas its aforementioned derivatives act as topoisomerase-II inhibitors [2]. However, their high toxicity, low water solubility, acquired drug resistance, and gastrointestinal disturbances have limited the applications of etoposide and teniposide in cancer chemotherapy [3]. In order to obtain better therapeutic agents, more diverse analogues like NK611, GL-311, NPF, etc. have been synthesized [4][5][6]. The numerous synthesized analogs have allowed improvement in the knowledge of structure-activity relationships. One of the major breakthroughs is the knowledge that the sugar moiety of etoposide is not essential for topoisomerase II inhibition. Synthetic studies on podophyllotoxin have showed that the O-linked (ethers, esters) and S-linked (thioethers) compounds are less active in comparison to the N-linked congeners [7].Indibulin is a novel, synthetic, small molecule with antitumor activity based upon destabilization of microtubules [8]. This clinical candidate is active against a variety of tumors in vitro and in vivo [9]. Furthermore, indibulin lacks the neurotoxicity typically associated with other tubulin-binding drugs such as the taxanes and vinca alkaloids, which might be related to its unknown tubulin-binding mode [9]. Both podophyllotoxin and indibulin are potent microtubulin inhibitors, but the indibulinbinding sites of the two compounds are different [10]. This prompted us to design hybrids of indibulin and podophyllotoxin with the aim of discovering novel tubulin inhibitors that can lower podophyllotoxincs toxicity by binding to a novel tubulinbinding domain.